Simultaneous intra/extravascular administration of antiproliferative agents as a new strategy to inhibit restenosis: The peak of reactive cell proliferation as a hallmark for the duration of the treatment
Open Access
- 18 January 2002
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 2 (1) , 1-10
Abstract
Strictly intravascular approaches for the treatment of postangioplasty restenosis are effective in the intima and the inner parts of the media but may be insufficient to control redundant pathways in the more outer parts of the media and the adventitia. An inverse situation may occur subsequently to a strictly extravascular approach, like the recently suggested pericardial approach in pigs. We hypothesized that simultaneous intra/extravascular administration of anti-restenotic agents inhibits restenosis by blocking all stimulatory pathways in the entire arterial wall. Fresh hearts of 25 domestic pigs were obtained from a local slaughterhouse. Left anterior descending coronary arteries (LAD) were harvested, cut into cylindric 5 mm segments, and cultured as ex vivo porcine organ cultures (POCs). After 9 bar ballooning simultaneous intra/extravascular administration of high dose diltiazem (50 μg/mL) was carried out for a period of 1, 2, 3, 4, 5, 6, and 7 days. At day 7 and 28 proliferative activity (BrdU), neointimal thickening, and staining against smooth muscle α-actin and vWF was analysed. 7 days after ballooning administration of diltiazem for 4, 5, 6, and 7 days inhibited reactive cell proliferation by more than 50% (n.s.) as compared to control, 28 days after ballooning administration for 6 and 7 days inhibited neointimal thickening by more than 75% (p < 0.05). Simultaneous intra/extravascular administration of high dose diltiazem did not affect the expression of vWF in endothelial cells or smooth muscle α-actin in smooth muscle cells. Simultaneous intra/extravascular administration of high dose diltiazem (50 μg/mL) has to be maintained for at least 6 days to achieve a significant inhibition of neointimal thickening. The data demonstrate the importance of the maximal reactive cell proliferation (= day 7 in the POC-model) for the calculation of the duration of the treatment period.Keywords
This publication has 22 references indexed in Scilit:
- Porous Balloon Delivery of S-dC28 Does Not Prevent Restenosis in the Porcine Coronary Artery Model of Balloon InjuryAntisense and Nucleic Acid Drug Development, 1999
- Minimally invasive access of the normal pericardium: Initial clinical experience with a novel deviceClinical Cardiology, 1999
- High-dose diltiazem prevents migration and prolifera vascular smooth muscle cells in various in-vitro mod human coronary restenosisCoronary Artery Disease, 1997
- A prescreening system for potential antiproliferative agents: implications for local treatment strategies of postangioplasty restenosisInternational Journal of Cardiology, 1995
- A coronary porcine organ culture system for studies of postangioplasty cell proliferationCoronary Artery Disease, 1995
- Effects of diltiazem on complications and restenosis after coronary angioplastyThe American Journal of Cardiology, 1991
- DiltiazemDrugs, 1990
- Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplastyAmerican Heart Journal, 1985
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984
- A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexesThe American Journal of Cardiology, 1984